雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Consultation status of chemotherapy-related lacrimal duct disorders at Kyushu University Hospital Ken-Ichi Takaki 1,2 , Mika Tanabe 1 , Masato Akiyama 1 , Kanako Yamana 1 , Koh-Hei Sonoda 1 1Department of Ophthalmology, Graduate School of Medicine, Kyushu University 2Takaki Ophthalmology Clinic pp.1104-1108
Published Date 2025/9/15
DOI https://doi.org/10.11477/mf.037055790790091104
  • Abstract
  • Look Inside
  • Reference

Abstract Purpose:Lacrimal drainage disorders associated with chemotherapy have become increasingly recognized due to the widespread use of the oral anticancer agent TS-1®. However, diagnosis and management require collaboration with other medical specialties. In this study, we investigated the clinical features of chemotherapy-related lacrimal drainage disorders treated at the Department of Ophthalmology, Kyushu University Hospital, and evaluated the state of interdepartmental collaboration.

Subjects and Methods:This study included 28 patients diagnosed with chemotherapy-related lacrimal drainage disorders who underwent lacrimal tube insertion at the Department of Ophthalmology, Kyushu University Hospital, between January 2014 and December 2018. Data on primary cancer sites and causative agents were extracted from medical records. Additionally, we analyzed the duration from symptom onset to treatment, the proportion of severe cases, and the referral pathways, categorizing cases as either “referral from other departments” or “direct ophthalmology visits.” These parameters were compared between two groups:the 2014-2016 cohort(15 cases) and the 2017-2018 cohort(13 cases).

Results:The mean age of the patients was 68.3±7.6 years, with gastric cancer being the most common primary site(46.4%). TS-1® alone accounted for 67.9% of the causative agents, while other combinations, including TS-1® with platinum agents, fluorouracil with docetaxel, and carboplatin with bevacizumab, were also identified. The proportion of referrals from other departments significantly increased from 33.3% in the 2014-2016 group to 76.9% in the 2017-2018 group(p=0.03). The median duration from symptom onset to treatment decreased from 6 months in the 2014-2016 group to 2 months in the 2017-2018 group, although this difference was not statistically significant(p=0.06).

Conclusion:While TS-1® was the most frequently implicated causative agent for chemotherapy-related lacrimal drainage disorders, other drugs were also involved. At Kyushu University Hospital, an increase in referrals from other departments and a reduction in the duration of symptoms before treatment suggested progress in interdepartmental collaboration.


Copyright © 2025, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 1882-1308 印刷版ISSN 0370-5579 医学書院

関連文献

  • 抗癌剤 千原 勤 医学書院 臨床婦人科産科
    32巻 5号 (1978年5月)
    pp.343-346
    • 有料閲覧
  • 抗癌剤 坂野 輝夫 , 木村 禧代二 医学書院 耳鼻咽喉科
    47巻 10号 (1975年10月)
    pp.777-787
    • 有料閲覧
  • 九州大学 有吉 朝美 医学書院 臨床泌尿器科
    21巻 4号 (1967年4月)
    pp.407
    • 有料閲覧
  • ③九州大学病院の場合 益田 宗幸 , 國武 直信 , 中島 寅彦 , 山下 弘之 , 熊本 芳彦 , 神宮 賢一 , 小宮山 荘太郎 医学書院 耳鼻咽喉科・頭頸部外科
    70巻 8号 (1998年7月)
    pp.483-486
    • 有料閲覧
  • 東北大学/九州大学 高橋 伸也 医学書院 臨床皮膚科
    21巻 6号 (1967年5月)
    pp.634-635
    • 有料閲覧
もっと見る

文献を共有